Currently, infigratinib is in a phase III study (NCT03773302) as first-line treatment for patients with cholangiocarcinoma harboring FGFR2 gene translocations, and in a phase I study (NCT04424966) in patients with high-grade glioma carrying FGFR3–TACC3 fusions [77]. Here, TACC3 is linked to central nervous system cancer.